TME Pharma

TME Pharma is a Berlin-based, publicly traded biotech advancing a novel approach to cancer treatment by targeting the tumor microenvironment. Its lead asset, NOX-A12, is a CXCL12-neutralizing Spiegelmer in Phase 2 development for glioblastoma, showing promising survival data in combination regimens. The company is pre-revenue, with a financial runway extending beyond 12 months as of early 2026, and faces the critical challenges of advancing late-stage trials and securing additional funding or partnerships.

Spiegelmer-based platform targeting chemokines (e.g., CXCL12, CCL2) in the tumor microenvironment (TME) to disrupt tumor protection and repair mechanisms.

TME Pharma competes in the crowded immuno-oncology and TME modulation space, facing competition from large pharma and biotech companies developing checkpoint inhibitors, angiogenesis inhibitors, and other TME-targeting agents. In glioblastoma specifically, it competes with standard chemoradiation, bevacizumab, and a pipeline of novel therapies targeting various mechanisms.